📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
15 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 lanouvellerepublique.fr · 26/02/2026
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQb1dnZUZ4YmZsdWhNRjJpaU53Tl9qSDh1TThSMFVxSkVhR2Zxb0lIYlhPU3RHMEQyZjVDYUZXeGR5ZlV2Mi1ocWNuNHpud2dyc1RZOXZVTFJlVUtLQy1jYnVjdzh5ZWJsaXFxZUdneWFwcTJCR0g4M240dENEazRpbVI2VEo3aXQzLXA2dVFnRUNKZDdYRURyT003UHcxZXZQV0VfQm5GU0Z1VDFobi1nSS1Sc2c2MDFVdj
Arthritis research & therapy · 2010
Abstract Introduction Tyrosine kinases are key mediators of multiple signaling pathways implicated in rheumatoid arthritis (RA). We previously demonstrated that imatinib mesylate--a Food and Drug Administration (FDA)-approved, antineoplastic drug that potently inhibits the tyrosine kinases Abl, c-Kit, platelet-derived growth factor receptor (PDGFR), and c-Fms--ameliorates murine autoimmune arthritis. However, which of the imatinib-targeted kinases is the principal culprit in disease pathogenesis remains unknown. Here we examine the role of c-Fms in autoimmune arthritis. Methods We tested the therapeutic efficacy of orally administered imatinib or GW2580, a small molecule that specifically inhibits c-Fms, in three mouse models of RA: collagen-induced arthritis (CIA), anti-collagen antibody-induced arthritis (CAIA), and K/BxN serum transfer-induced arthritis (K/BxN). Efficacy was evaluated by visual scoring of arthritis severity, paw thickness measurements, and histological analysis. We assessed the in vivo effects of imatinib and GW2580 on macrophage infiltration of synovial joints in CIA, and their in vitro effects on macrophage and osteoclast differentiation, and on osteoclast-mediated bone resorption. Further, we determined the effects of imatinib and GW2580 on the ability of macrophage colony-stimulating factor (M-CSF; the ligand for c-Fms) to prime bone marrow-derived macrophages to produce tumor necrosis factor (TNF) upon subsequent Fc receptor ligation. Finally, we measured M-CSF levels in synovial fluid from patients with RA, osteoarthritis (OA), or psoriatic arthritis (PsA), and levels of total and phosphorylated c-Fms in synovial tissue from patients with RA. Results GW2580 was as efficacious as imatinib in reducing arthritis severity in CIA, CAIA, and K/BxN models of RA. Specific inhibition of c-Fms abrogated (i) infiltration of macrophages into synovial joints of arthritic mice; (ii) differentiation of monocytes into macrophages and osteoclasts; (iii) osteoclast-mediated bone resorption; and (iv) priming of macrophages to produce TNF upon Fc receptor stimulation, an important trigger of synovitis in RA. Expression and activation of c-Fms in RA synovium were high, and levels of M-CSF were higher in RA synovial fluid than in OA or PsA synovial fluid. Conclusions These results suggest that c-Fms plays a central role in the pathogenesis of RA by mediating the differentiation and priming of monocyte lineage cells. Therapeutic targeting of c-Fms could provide benefit in RA.
Drug safety · 2021
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Immunological investigations · 2014 · Journal Article
Novaes E Brito RR, Xander P, Pérez EC, Maricato JT, et al.
Immunology · 2008 · Journal Article
Postól E, Meyer A, Cardillo F, de Alencar R, et al.
Journal of clinical laboratory analysis · 1997 · Journal Article
Harima HA, Mendes NF, Mamizuka EM, Mariano M
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 1990 · Journal Article
Baccaro MR, Mariano M, Malucelli BE
Haematologica · 1988 · Case Reports
Grottolo A, Ferrari V, Mariano M, Zambruni A, et al.
International journal of immunogenetics · 2021 · Journal Article
Lima SC, Gomes da Silva IIF, Nascimento DQ, de Moura RR, et al.
Lupus · 2007 · Journal Article
e Brito RR, De Lorenzo BH, Xander P, Godoy LC, et al.
BMC pediatrics · 2013 · Journal Article
do Monte FA, Ferreira MN, Petribu KC, Almeida NC, et al.
Clinical, cosmetic and investigational dentistry · 2021 · Journal Article
Souza RC, de Sousa ET, Sousa D, Sales M, et al.
Arthritis research & therapy · 2010 · Journal Article
Paniagua RT, Chang A, Mariano MM, Stein EA, et al.
Haematologica · 2018 · Journal Article
Lam C, Ferguson ID, Mariano MC, Lin YT, et al.
Nursing outlook · 2025 · Journal Article
Mariano MA, Tomori C
Drug safety · 2021 · Journal Article
Silvestri M, Cristaudo A, Morrone A, Messina C, et al.
Revista da Associacao Medica Brasileira (1992) · 2015 · Journal Article
Azevedo AF, Petribú KC, Lima Mde N, Silva AS, et al.
Drug safety · 2021 · Journal Article
Silvestri M, Cristaudo A, Morrone A, Messina C, et al.
Drug safety · 2021 · Journal Article
Silvestri M, Cristaudo A, Morrone A, Messina C, et al.
Rheumatology international · 2012 · Clinical Trial
Giuggioli D, Colaci M, Manfredi A, Mariano M, et al.